Functional imaging-guided carbon ion irradiation with simultaneous integrated boost for localized prostate cancer: study protocol for a phase II randomized controlled clinical trial

Wei Hu, Ping Li, Zhengshan Hong, Xiaomao Guo, Yulei Pei, Zhenshan Zhang, Qing Zhang, Wei Hu, Ping Li, Zhengshan Hong, Xiaomao Guo, Yulei Pei, Zhenshan Zhang, Qing Zhang

Abstract

Background: Due to the physical dose distribution characteristic of "Bragg peak" and the biological effect as a kind of high linear energy transfer ray, heavy ion therapy has advantages over conventional photon therapy in both efficacy and safety. Based on the evidence that prostate cancer lesions before treatment are the most common sites of tumor residual or recurrence after treatment, simultaneous integrated boost radiation therapy for prostate cancer has been proven to have the advantage of improving efficacy without increasing toxicities.

Methods: This study is a prospective phase II randomized controlled clinical trial evaluating the efficacy and safety of functional imaging-guided carbon ion irradiation with simultaneous integrated boost for localized prostate cancer. One hundred and forty patients with localized prostate cancer will be randomized into carbon ion radiotherapy group and simultaneous integrated boost carbon ion radiotherapy group at a 1:1 ratio. The primary endpoint is to compare the incidence of treatment-related grade 2 and higher acute toxicities between the two groups according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. Secondary endpoints are late toxicities, biochemical relapse-free survival, overall survival, progression-free survival, and quality of life.

Discussion: This study adopts functional imaging-guided simultaneous integrated boost of carbon ion radiotherapy for localized prostate cancer, aiming to evaluate the differences in the severity and incidence of acute toxicities in patients with localized prostate cancer treated with carbon ion radiotherapy and simultaneous integrated boost carbon ion radiotherapy, in order to optimize the carbon ion treatment strategy for localized prostate cancer.

Trial registration: ClinicalTrials.gov NCT05010343. Retrospectively registered on 18 August 2021.

Keywords: Carbon ion radiotherapy; PSMA PET/CT; Prostate cancer; Simultaneous integrated boost; mpMRI.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
The flow chart of the current trial

References

    1. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(1):67–74.
    1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): prostate cancer. . Accessed 9 Feb 2021.
    1. Brenner DJ, Martinez AA, Edmundson GK, et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys. 2002;52:6–13.
    1. D'Souza WD, Thames HD. Is the alpha/beta ratio for prostate cancer low? Int J Radiat Oncol Biol Phys. 2001;51:1–3.
    1. Fowler JF, Ritter MA, Chappell RJ, et al. What hypofractionated protocols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys. 2003;56:1093–1104.
    1. Al-Mamgani A, van Putten WL, Heemsbergen WD, et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;72(4):980–988.
    1. Hou Z, Li G, Bai S. High dose versus conventional dose in external beam radiotherapy of prostate cancer: a meta-analysis of long-term follow-up. J Cancer Res Clin Oncol. 2015;141(6):1063–1071.
    1. Schulz-Ertner D, Tsujii H. Particle radiation therapy using proton and heavier ion beams. J Clin Oncol. 2007;25(8):953–964.
    1. Minohara S, Fukuda S, Kanematsu N, et al. Recent innovations in carbon-ion radiotherapy. J Radiat Res. 2010;51(4):385–392.
    1. Shirai K, Saitoh JI, Musha A, et al. Working Group on Head and Neck Tumors. Prospective observational study of carbon-ion radiotherapy for non-squamous cell carcinoma of the head and neck. Cancer Sci. 2017;108(10):2039–2044.
    1. Demizu Y, Jin D, Sulaiman NS, Nagano F, et al. Particle Therapy Using Protons or Carbon Ions for Unresectable or Incompletely Resected Bone and Soft Tissue Sarcomas of the Pelvis. Int J Radiat Oncol Biol Phys. 2017;98(2):367–374.
    1. Yamamoto N, Miyamoto T, Nakajima M, et al. A dose escalation clinical trial of single-fraction carbon ion radiotherapy for peripheral stage I non-small cell lung cancer. J Thorac Oncol. 2017;12(4):673–680.
    1. Ishikawa H, Tsuji H, Murayama S, et al. Particle therapy for prostate cancer: the past, present and future. Int J Urol. 2019;26(10):971–979.
    1. Okada T, Tsuji H, Kamada T, et al. Carbon ion radiotherapy in advanced hypofractionated regimens for prostate cancer: from 20 to 16 fractions. Int J Radiat Oncol Biol Phys. 2012;84:968–972.
    1. Nomiya T, Tsuji H, Kawamura H, et al. A multi-institutional analysis of prospective studies of carbon ion radiotherapy for prostate cancer: a report from the Japan Carbon ion Radiation Oncology Study Group (J-CROS) Radiother Oncol. 2016;121(2):288–293.
    1. Mohamad O, Tabuchi T, Nitta Y, et al. Risk of subsequent primary cancers after carbon ion radiotherapy, photon radiotherapy, or surgery for localised prostate cancer: a propensity score-weighted, retrospective, cohort study. Lancet Oncol. 2019;20(5):674–685.
    1. Sato H, Kasuya G, Ishikawa H, et al. Long-term clinical outcomes after 12-fractionated carbon-ion radiotherapy for localized prostate cancer. Cancer Sci. 2021;112(9):3598–3606.
    1. Fowler J, Chappell R, Ritter M. Is α/β for prostate tumors really low? Int J Radiat Oncol Biol Phys. 2001;50:1021–1031.
    1. Pucar D, Hricak H, Shukla-Dave A, et al. Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor magnetic resonance imaging and step-section pathology evidence. Int J Radiat Oncol Biol Phys. 2007;69(1):62–69.
    1. Arora R, Koch MO, Eble JN, et al. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer. 2004;100(11):2362–2366.
    1. Sanmamed N, Lee J, Berlin A, et al. Tumor-targeted dose escalation for localized prostate cancer using MR-guided HDR brachytherapy (HDR) or integrated VMAT(IB-VMAT) boost: Dosimetry, toxicity and health related quality of life. Radiother Oncol. 2020;149:240–245.
    1. Viani GA, Stefano EJ, Afonso SL. Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys. 2009;74(5):1405–1418.
    1. Thames HD, Schultheiss TE, Hendry JH, et al. Can modest escalations of dose be detected as increased tumor control? Int J Radiat Oncol Biol Phys. 1992;22:241–246.
    1. Tomé WA, Fowler JF. Selective boosting of tumor subvolumes. Int J Radiat Oncol Biol Phys. 2000;48:593–599.
    1. Kim Y, Tome WA. Is it beneficial to selectively boost high-risk tumor subvolumes? A comparison of selectively boosting high-risk tumor subvolumes versus homogeneous dose escalation of the entire tumor based on equivalent EUD plans. Acta Oncol. 2008;47(5):906–916.
    1. Hardcastle N, Tome WA. Risk-adaptive volumetric modulated arc therapy using biological objective functions for subvolume boosting in radiotherapy. Comput Math Methods Med. 2012;2012:348471.
    1. Onal C, Topkan E, Efe E, et al. Comparison of rectal volume definition techniques and their influence on rectal toxicity in patients with prostate cancer treated with 3D conformal radiotherapy: a dose-volume analysis. Radiat Oncol. 2009;4:14.
    1. Ghadjar P, Vock J, Vetterli D, et al. Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking. Radiat Oncol. 2008;3:35.
    1. Fonteyne V, Villeirs G, Speleers B, et al. Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion. Int J Radiat Oncol Biol Phys. 2008;72(3):799–807.
    1. Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2021;79(2):243–262.
    1. Barentsz JO, Richenberg J, Clements R, et al. ESUR prostate MR guidelines 2012. Eur Radiol. 2012;22(4):746–757.
    1. Metcalfe P, Liney GP, Holloway L, et al. The potential for an enhanced role For MRI in radiation-therapy treatment planning. Technol Cancer Res Treat. 2013;12(5):429–446.
    1. Zhen L, Liu X, Yegang C, et al. Accuracy of multiparametric magnetic resonance imaging for diagnosing prostate cancer: a systematic review and meta-analysis. BMC Cancer. 2019;19(1):1244.
    1. Perera M, Papa N, Christidis D, et al. Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;70(6):926–937.
    1. Han S, Woo S, Kim YJ, et al. Impact of 68Ga-PSMA PET on the management of patients with prostate cancer: a systematic review and meta-analysis. Eur Urol. 2018;74(2):179–190.
    1. Niyazi M, Bartenstein P, Belka C, et al. Choline PET based dose-painting in prostate cancer--modelling of dose effects. Radiat Oncol. 2010;5:23.
    1. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. . Accessed 14 June 2010.
    1. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) Int J Radiat Oncol Biol Phys. 1995;31(5):1341–1346.
    1. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53(5):1097–1105.
    1. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005;294(10):1233–1239.
    1. Peeters ST, Heemsbergen WD, Koper PC, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006;24(13):1990–1996.
    1. Beckendorf V, Guerif S, Le Prisé E, et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys. 2011;80(4):1056–1063.
    1. Heemsbergen WD, Al-Mamgani A, Slot A, et al. Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiother Oncol. 2014;110(1):104–109.
    1. Ma TM, Lilleby O, Lilleby WA, et al. Ablative radiotherapy in prostate cancer: stereotactic body radiotherapy and high dose rate brachytherapy. Cancers (Basel) 2020;12(12):3606.
    1. Yoshioka Y, Yoshida K, Yamazaki H, et al. The emerging role of high-dose-rate (HDR) brachytherapy as monotherapy for prostate cancer. J Radiat Res. 2013;54(5):781–788.
    1. Demanes DJ, Ghilezan MI. High-dose-rate brachytherapy as monotherapy for prostate cancer. Brachytherapy. 2014;13(6):529–541.
    1. Tsujii H, Mizoe JE, Kamada T, et al. Overview of clinical experiences on carbon ion radiotherapy at NIRS. Radiother Oncol. 2004;73(Suppl 2):S41–S49.
    1. Tsuji H, Yanagi T, Ishikawa H, et al. Hypofractionated radiotherapy with carbon ion beams for prostate cancer. Int J Radiat Oncol Biol Phys. 2005;63(4):1153–1160.
    1. Lee R, Yamada S, Yamamoto N, et al. Chromosomal aberrations in lymphocytes of lung cancer patients treated with carbon ions. J Radiat Res. 2004;45:195–199.
    1. Alphonse G, Maalouf M, Battiston-Montagne P, et al. p53-independent early and late apoptosis is mediated by ceramide after exposure of tumor cells to photon or carbon ion irradiation. BMC Cancer. 2013;13:151.
    1. Ferrandon S, Magné N, Battiston-Montagne P, et al. Cellular and molecular portrait of eleven human glioblastoma cell lines under photon and carbon ion irradiation. Cancer Lett. 2015;360(1):10–16.
    1. Matsunaga A, Ueda Y, Yamada S, et al. Carbon-ion beam treatment induces systemic antitumor immunity against murine squamous cell carcinoma. Cancer. 2010;116(15):3740–3748.
    1. Ran J, Wang J, Dai Z, et al. Irradiation-induced changes in the immunogenicity of lung cancer cell lines: based on comparison of X-rays and carbon ions. Front Public Health. 2021;9:666282.
    1. Chiblak S, Tang Z, Lemke D, et al. Carbon irradiation overcomes glioma radioresistance by eradicating stem cells and forming an antiangiogenic and immunopermissive niche. JCI Insight. 2019;4(2):e123837.
    1. Cellini N, Morganti AG, Mattiucci GC, et al. Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. Int J Radiat Oncol Biol Phys. 2002;53(3):595–599.
    1. Lips IM, van der Heide UA, Haustermans K, et al. Single blind randomized Phase III trial to investigate the benefifit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): study protocol for a randomized controlled trial. Trials. 2011;12:255.
    1. Wong WW, Schild SE, Vora SA, et al. Image-guided radiotherapy for prostate cancer: a prospective trial of concomitant boost using indium-111-capromab pendetide (ProstaScint) imaging. Int J Radiat Oncol Biol Phys. 2011;81(4):e423–e429.
    1. Pinkawa M, Piroth MD, Holy R, et al. Dose-escalation using intensity-modulated radiotherapy for prostate cancer-evaluation of quality of life with and without (18)F-choline PET-CT detected simultaneous integrated boost. Radiat Oncol. 2012;7:14.
    1. Kerkmeijer LGW, Groen VH, Pos FJ, et al. Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial. J Clin Oncol. 2021;39(7):787–796.
    1. van Lin EN, Futterer JJ, Heijmink SW, et al. IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. Int J Radiat Oncol Biol Phys. 2006;65(1):291–303.
    1. START Trialists’ Group. Bentzen SM, Agrawal RK, et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008;371(9618):1098–1107.
    1. START Trialists’ Group. Bentzen SM, Agrawal RK, et al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol. 2008;9(4):331–341.
    1. Lester JF, Macbeth FR, Toy E, et al. Palliative radiotherapy regimens for non-small cell lung cancer. Cochrane Database Syst Rev. 2006;(4):CD002143.
    1. Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17(8):1047–1060.
    1. Lee WR, Dignam JJ, Amin MB, et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol. 2016;34(20):2325–2332.
    1. Catton CN, Lukka H, Gu CS, et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol. 2017;35(17):1884–1890.
    1. Widmark A, Gunnlaugsson A, Beckman L, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019;394(10196):385–395.
    1. Brand DH, Tree AC, Ostler P, et al. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol. 2019;20(11):1531–1543.
    1. Hickey BE, James ML, Daly T, et al. Hypofractionation for clinically localized prostate cancer. Cochrane Database Syst Rev. 2019;9(9):CD011462.
    1. Herrera FG, Valerio M, Berthold D, et al. 50 Gy Stereotactic body radiation therapy to the dominant intra-prostatic nodule: results from a phase Ia/b trial. Int J Radiat Oncol Biol Phys. 2019;103(2):320–334.
    1. Draulans C, van der Heide UA, Haustermans K, et al. Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer. Radiother Oncol. 2020;147:92–98.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する